In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.75, demonstrating a -5.89% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday. Recursion Pharmaceuticals soared by 13.99 ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 26,086 calls trading, 1.1x expected, and implied vol increasing almost 32 points to 119.88%. 10/31 weekly 6 calls and Oct-25 5.5 ...

Recursion Pharmaceuticals NASDAQ:RXRX Chief Executive Officer Christopher Gibson sold 100,000 shares of Class A Common Stock on October 23, 2025, at a price of $5.70, totaling $570,000. The sale ...

Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common ...

The Florida government is ridding the Everglades of invasive pythons by allowing fashion brans to turn them into luxury accessories. Inverse Leathers Shopping will now save the planet. Florida ...